Ranibizumab BS Senju
Ranibizumab biosimilar developed by Senju Pharmaceutical. Reference product Lucentis.
Brands by market: Ranibizumab BS Senju (Japan) · Commercial partner or holder: Senju Pharmaceutical · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDASep 2021approved
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Ranibizumab BS Senju
Ranibizumab BS Senju is Senju Pharmaceutical's ranibizumab, the first and so far only ranibizumab biosimilar approved in Japan, in September 2021. Senju is a Japanese eye-care specialist and has not named the developer of the product.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan · Ranibizumab BS Senju
Pharmaceuticals and Medical Devices Agency and MHLWApprovedBrand
Ranibizumab BS Senju
Holder or applicant
Senju Pharmaceutical
Pathway
Biosimilar (MHLW approval on PMDA review)
Approved
Sep 2021
Indications as licensed
Wet AMD, myopic CNV
Presentations
10 mg/mL intravitreal kit
Remarks
Ranibizumab Biosimilar 1, the first in Japan.
Source
S020 (PMDA) · checked Sep 2026
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- PMDASep 2021Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning ranibizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.